The Administrative Committee of Changzhou West Taihu Lake Science and Technology Zone has formalized a strategic partnership with Paitai Biotechnology (Changzhou) Co., Ltd. during a signing ceremony held on November 14. This collaboration will facilitate the establishment of a cutting-edge pilot R&D base for peptide drug intermediates, fostering innovation in biopharmaceutical development and industrial application. Deputy Mayor Jiang Pengju attended the ceremony as a witness to this landmark agreement.
Paitai Biotechnology specializes in the biosynthesis and engineering of protein- and peptide-based drugs, as well as functional compounds derived from natural plants. Among its flagship innovations is a synthetic biology process for GLP-1, the active pharmaceutical ingredient (API) in semaglutide. This compound has shown remarkable efficacy in treating diabetes, promoting weight loss, and addressing cardiovascular conditions. The company has already scaled up production to industrial levels, utilizing 1-ton fermentation tanks.
Beyond semaglutide, Paitai Biotechnology is advancing a diverse product portfolio targeting biomedicine, agriculture, and food sectors. Key developments include astaxanthin, phosphatidylserine (PS), and glutathione, supported by strategic investment from Future Capital.
Construction of the first phase of the R&D facility in West Taihu Lake is on track to conclude by mid-2025, with equipment testing to follow. The facility is expected to begin production later that year, marking a significant milestone for Changzhou's biopharmaceutical ambitions.
扫一扫在手机打开当前页  |
